News

    Aptahem AB (publ) offentliggör memorandum avseende företrädesemissionen

    2022-11-17

    EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...

    Read More

    Aptahem receives full regulatory approval to start the FIH study with Apta-1

    2022-11-10

    Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, has today received approval from the central ethics committee and the competent authorities in the Netherlands to start a clinical First...

    Read More

    BioStock article: Aptahem’s CEO comments on the rights issue

    2022-11-10

    BioStock published an article on 10 November 2022 about Aptahem, which can be read in full below. Biotechnology company Aptahem’s report for the third quarter of 2022 focuses on the progress made on the way to the major milestone,...

    Read More

    BioStock article: Aptahem provides an operational update

    2022-10-31

    BioStock published an article on 31 October 2022 about Aptahem, which can be read in full below. Aptahem is nudging closer to its biggest milestone as a listed biotech company – the first clinical studies with Apta-1, a drug...

    Read More

    BioStock article: Aptahem on the application to initiate clinical studies

    2022-09-26

    BioStock published an article on 26 September 2022 about Aptahem, which can be read in full below. Aptahem has submitted applications to the regulatory authorities and to the Central Ethics Committee in the Netherlands for permission to start a...

    Read More

    Aptahem submit regulatory approval to initiate clinical phase 1 study

    2022-09-19

    Aptahem AB (publ) announce today that applications to the regulatory authority and the central ethics committee in The Netherlands have been submitted for approval to initiate a clinical phase 1 study with its drug candidate Apta-1. Aptahem develop Apta-1...

    Read More

    BioStock article: Aptahem on the importance of raising sepsis awareness

    2022-09-16

    BioStock published an article on 16 September 2022 about Aptahem, which can be read in full below. Sepsis is a life-threatening condition. Every year, 50 million people are affected by sepsis, of which 11 million die. Despite this, a...

    Read More

    BioStock article: Aptahem on schedule for clinical studies

    2022-08-31

    BioStock published an article on 31 August 2022 about Aptahem, which can be read in full below. Malmö-based biotech Aptahem, which is developing the drug candidate Apta-1 as a new type of emergency treatment for sepsis, released its Q2...

    Read More

    BioStock article: Aptahem increasingly close to clinical studies

    2022-08-15

    BioStock published an article on 15 August 2022 about Aptahem, which can be read in full below. BioStock reached out to Malmö company Aptahem, which is developing an emergency treatment for sepsis. The biotech points out that they continue...

    Read More

    Aptahem confirms that lead candidate Apta-1 shows very good tolerability in the GLP tox studies

    2022-06-23

    Aptahem AB (publ) announces today that the final study report from the GLP (Good Laboratory Practice) toxicology and safety studies has been finalized. The report confirms the previously communicated preliminary results regarding positive safety profile for Apta-1. The GLP...

    Read More